STOCK TITAN

Ingredion’s 595 pence All-Cash Offer to Acquire Tate & Lyle Accepted by Their Shareholders

(Neutral)
(Positive)

Ingredion (NYSE: INGR) confirmed that shareholders of Tate & Lyle have accepted its recommended 595 pence per share all-cash offer for the entire issued and to be issued share capital of Tate & Lyle, originally announced on June 8, 2026.

According to Ingredion, the transaction is expected to generate approximately $130 million in run-rate net cost synergies, fully realized by the end of 2030, and to be adjusted EPS accretive in the first year following completion. Regulatory review and clearance are ongoing, and the companies will continue to operate separately until closing, which is currently expected in the second half of 2027.

Loading...
Loading translation...

Positive

  • 595 pence per share all-cash offer for Tate & Lyle’s entire share capital, now accepted by shareholders
  • Expected run-rate net cost synergies of approximately $130 million by end of 2030
  • Projected adjusted EPS accretion for Ingredion shareholders in the first year post-completion

Negative

  • Transaction closing only expected in the second half of 2027, implying a long timeline to realize benefits
  • Completion remains subject to ongoing regulatory review and required clearances, creating closing uncertainty

News Market Reaction – INGR

-0.94%
-0.94% Session close to close

In the Jul 29 session, INGR declined 0.94%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

INGR’s acquisition history recorded -0.32% and -0.62% 24-hour reactions. Against that record, shareh...
Analysis

INGR’s acquisition history recorded -0.32% and -0.62% 24-hour reactions. Against that record, shareholder acceptance marks progress, but regulatory clearance and the active S-3ASR debt shelf remain the key items to watch.

Key Figures

Offer price: 595 pence per share Net cost synergies: $130 million EPS accretion timing: First year +2 more
5 metrics
Offer price 595 pence per share All-cash offer for Tate & Lyle
Net cost synergies $130 million Run-rate synergies expected fully realized by the end of 2030
EPS accretion timing First year Adjusted EPS accretion following transaction completion
Expected completion H2 2027 Subject to regulatory conditions
Synergy realization 2030 Expected end date for full realization of run-rate net cost synergies

Previous Acquisition Reports

2 past events · Latest: Jun 08 (Positive)
Same Type Pattern 2 events
Date Event Sentiment 24h Move Catalyst
Jun 08 Recommended cash acquisition Positive -0.3% Recommended all-cash acquisition announced with targeted cost synergies and first-year EPS accretion.
Jun 02 Asset acquisition Positive -0.6% Prebiotic fiber asset acquisition expanded Ingredion’s ingredient portfolio.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Both tag-matched acquisition announcements were followed by negative 24-hour reactions, with an average move of -0.47%.

Key Terms

all-cash offer, run-rate net cost synergies, adjusted EPS accretion
3 terms
all-cash offer financial
"have today accepted the terms of a recommended all-cash offer"
An all-cash offer is a proposal to buy a company using only cash rather than stock or other securities, like buying a house outright instead of taking a mortgage or trading part of its value. For investors this matters because cash deals typically provide faster, more certain payment and remove the risk of buyer financing or share dilution, often affecting takeover odds and the target’s stock price reaction.
run-rate net cost synergies financial
"This includes run-rate net cost synergies of approximately $130 million"
The annualized amount of ongoing cost savings a combined company expects to achieve after a merger or restructuring, measured after subtracting one-time integration expenses and any recurring costs that offset those savings. Think of it like two households merging budgets: the run-rate net cost synergies are the steady yearly savings you expect once all changes are in place. Investors use this to judge how a deal will affect future profits and cash flow.
adjusted EPS accretion financial
"as well as adjusted EPS accretion to Ingredion shareholders"
Adjusted EPS accretion measures how much a company's earnings per share (EPS) would rise after removing one-time items and including expected recurring effects of an event, such as a merger or cost savings; it compares pro forma, or adjusted, EPS before and after the event. It matters because it gives a cleaner view of whether a transaction or change will increase per-share earnings, similar to checking a car's fuel efficiency after removing unusual trips to see the true improvement.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
  • Tate & Lyle shareholders accept Ingredion’s recommended cash offer
  • Shareholder acceptance marks an important milestone toward creating a global ingredient solutions leader with enhanced innovation and formulation capabilities
  • Closing expected in H2 2027, subject to the satisfaction of regulatory conditions

WESTCHESTER, Ill., July 28, 2026 (GLOBE NEWSWIRE) -- Ingredion Incorporated (NYSE: INGR) (“Ingredion”), a leading global provider of ingredient solutions for food, beverage, pharmaceutical, personal care, and industrial applications, confirms that shareholders of Tate & Lyle PLC (“Tate & Lyle”), a global leader in mouthfeel, sweetening and fortification, have today accepted the terms of a recommended all-cash offer by Ingredion for the entire issued and to be issued share capital of Tate & Lyle, as announced on June 8, 2026.

“We are pleased that, at the recommendation of their Board of Directors, Tate & Lyle shareholders have accepted Ingredion’s all-cash offer to acquire all of the issued and outstanding shares of Tate & Lyle,” said Jim Zallie, chairman, president and CEO of Ingredion. “Today marks an important milestone toward establishing a global leader in ingredient solutions that will help create the future of food.”

The transaction is expected to deliver significant financial benefits and value creation. This includes run-rate net cost synergies of approximately $130 million, expected to be fully realized by the end of 2030, as well as adjusted EPS accretion to Ingredion shareholders in the first year following completion and an enhanced long-term growth profile and earnings potential for the combined group.

Regulatory review and clearance, as set out in the scheme document, is ongoing. As the regulatory review process progresses, Ingredion remains focused on securing the required approvals as efficiently as possible, while continuing to operate as a separate business from Tate & Lyle until completion of the transaction which is expected in the second half of 2027.

Zallie continued, “By combining the complementary capabilities of Ingredion and Tate & Lyle, we will strengthen our ability to help customers solve complex formulation challenges with an expanded innovation engine to accelerate product development and deliver the great-tasting, healthy and affordable food products that consumers want and deserve. As we work toward completing the transaction, we remain focused on serving customers with the quality, reliability and support they expect.”

For more information, please visit https://www.ingredion.com/na/en-us/legal/offer-communications.

Forward-Looking Statements

This press release contains or may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Ingredion intends these forward-looking statements to be covered by the safe harbor provisions for such statements.

Forward-looking statements in this press release include statements regarding Ingredion’s expectations with respect to completion and benefits of Ingredion’s recommended all-cash offer for the issued and to be issued share capital of Tate & Lyle (the “Acquisition”), including statements regarding plans, objectives, intentions and expectations with respect to completion of the Acquisition and the future operations and financial performance of the combined group. Forward-looking statements also include, among others, any other statements regarding Ingredion’s prospects and Ingredion’s future operations, financial condition, volumes, cash flows, expenses or other financial items, including management’s plans or strategies and objectives for any of the foregoing and any assumptions, expectations, or beliefs underlying any of the foregoing.

These statements can sometimes be identified by the use of forward-looking words such as “may,” “will,” “should,” “anticipate,” “assume,” “believe,” “plan,” “project,” “estimate,” “expect,” “intend,” “continue,” “pro forma,” “forecast,” “outlook,” “opportunities,” “potential,” or other similar expressions or the negative thereof. All statements other than statements of historical facts therein are “forward-looking statements.”

These statements are based on current circumstances or expectations, but are subject to certain inherent risks and uncertainties, many of which are difficult to predict and beyond Ingredion’s control. Although Ingredion believes its expectations reflected in these forward-looking statements are based on reasonable assumptions, investors are cautioned that no assurance can be given that Ingredion’s expectations will prove correct.

The following factors relating to the Acquisition, among others, could cause actual results to differ materially from those expressed in or implied by Ingredion’s forward-looking statements: failure of the Acquisition to be completed when expected or at all because of the inability to satisfy material antitrust or other conditions or for other reasons; the risk that the expected benefits of the Acquisition may not be fully realized or may take longer to realize that anticipated, including as a result of the risks and uncertainties discussed below; failure to integrate effectively the businesses of Ingredion and Tate & Lyle or to manage effectively the expanded operations of the combined group; and the incurrence of substantial expenses and indebtedness by Ingredion and the combined group to complete the Acquisition and to operate the enterprise after completion.

Additional risks and uncertainties that could cause actual results and developments to differ materially from the expectations expressed in or implied by Ingredion’s forward-looking statements include, among others: changes in consumer practices, preferences, price sensitivity, behaviors, demand and perceptions; the impact of geopolitical developments, tensions, threats or conflicts on the availability and prices of raw materials and energy supplies, supply chains and foreign exchange and interest rates; the impact of global business and economic conditions on demand for Ingredion’s products or Ingredion’s access to global credit and equity markets; Ingredion’s reliance on certain industries for a significant portion of Ingredion’s sales; operating difficulties at Ingredion’s manufacturing facilities and liabilities relating to product safety and quality; Ingredion’s ability to keep pace with technological developments in research and development and continue to offer innovative products; competitive pressures that may adversely affect Ingredion’s market share, revenue and profitability; market volatility that may adversely affect Ingredion’s ability to pass through potential increases in the cost of corn and other raw materials to customers, to purchase quantities of corn and other raw materials at prices sufficient to sustain or increase Ingredion’s profitability, or to supply product quantities and meet shipment delivery requirements that Ingredion’s customers demand; the impact on inputs to Ingredion’s procurement, production processes and delivery channels, such as raw material, energy, and freight and logistics, of price fluctuations, supply chain interruptions, tariffs, duties, and shortages; Ingredion’s ability to contain costs, manage working capital, and achieve budgets, including completion of planned maintenance and investment projects on time and on budget; global climate change and legal, regulatory, or market measures to address climate change; Ingredion’s ability to identify and complete acquisitions, divestitures, or strategic alliances on favorable terms or achieve anticipated synergies; the economic, political and other risks inherent in conducting operations in foreign countries and with foreign currencies; Ingredion’s ability to maintain satisfactory labor relations; Ingredion’s ability to attract, develop, retain, motivate and maintain good relationships with its workforce, including key personnel; the impact of legal and regulatory proceedings; the risks associated with pandemics; the impact of any impairment charges on intangible assets and goodwill; global and regional economic policies and changes to existing laws and regulations; changes in Ingredion’s tax rates or exposure to additional income tax liabilities; increases in interest rates that could increase Ingredion’s borrowing costs; risks affecting Ingredion’s ability to raise funds at reasonable rates and other factors affecting Ingredion’s access to sufficient funds for future growth and expansion; risks relating to the use of artificial intelligence and other advanced technologies, and Ingredion’s reliance on third party technology providers; interruptions, security incidents, or failures with respect to information technology systems, processes, and sites; risks affecting the continuation of Ingredion’s dividend policy; and Ingredion’s ability to maintain effective internal control over financial reporting.

Ingredion’s forward-looking statements speak only as of the date on which they are made, and Ingredion does not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of the statement as a result of new information or future events or developments or otherwise. If Ingredion does update or correct one or more of these statements, investors and others should not conclude that Ingredion will make additional updates or corrections. For a further description of these and other risks, see “Risk Factors” and other information included in Ingredion’s Annual Report on Form 10-K for the year ended December 31, 2025 and in Ingredion’s subsequent reports on Form 10-Q and Form 8-K filed with the Securities and Exchange Commission.

About Ingredion Incorporated

Ingredion Incorporated (NYSE: INGR), headquartered in the suburbs of Chicago, is a leading global ingredient solutions provider serving customers in more than 120 countries. With 2025 annual net sales of approximately $7.2 billion, Ingredion turns grains, fruits, vegetables and other plant-based materials into value-added ingredient solutions for the food, beverage, animal nutrition, brewing, pharmaceutical and industrial markets. With Ingredion’s Idea Labs® innovation centers around the world and more than 11,000 employees, Ingredion co-creates with customers and fulfills its purpose of bringing the potential of people, nature and technology together to make life better. Visit ingredion.com for more information and the latest Ingredion news.

Contacts:

Media Relations:

In the U.S.:
Jayne Rosefield / Dave Carlson
+1 312 800 8120

In the U.K.:
Charles Pretzlik / Ed Brown / David Blackburn
+44 20 7404 5959

INGREDION@brunswickgroup.com

Investor Relations:

Noah Weiss, 773-896-5242


FAQ

What are the key terms of Ingredion’s 595 pence all-cash offer for Tate & Lyle (NYSE: INGR)?

Ingredion has offered 595 pence in cash per Tate & Lyle share for the company’s entire issued and to be issued share capital. According to Ingredion, Tate & Lyle’s shareholders have now accepted this recommended all-cash offer, progressing the proposed acquisition.

When is Ingredion’s acquisition of Tate & Lyle expected to close for INGR investors?

Ingredion expects the Tate & Lyle acquisition to close in the second half of 2027, subject to regulatory conditions. According to Ingredion, regulatory review and clearance are ongoing, and both companies will continue operating as separate businesses until completion of the transaction.

What financial benefits does Ingredion expect from acquiring Tate & Lyle (INGR)?

Ingredion expects the transaction to deliver approximately $130 million in run-rate net cost synergies by the end of 2030. According to Ingredion, the deal is also projected to be adjusted EPS accretive in the first year after completion and to enhance long-term growth and earnings potential.

How will the Tate & Lyle acquisition affect Ingredion’s earnings (NYSE: INGR)?

Ingredion expects the acquisition to be adjusted EPS accretive in the first year following completion. According to Ingredion, combining the businesses should support an improved long-term growth profile and earnings potential for the combined group, alongside the planned cost synergies.

What regulatory approvals are required for Ingredion’s Tate & Lyle deal (INGR)?

The acquisition remains subject to regulatory review and required clearances set out in the scheme document. According to Ingredion, the regulatory process is ongoing, and the company is focused on securing these approvals as efficiently as possible before the expected closing in the second half of 2027.

Why do Tate & Lyle shareholders support Ingredion’s all-cash offer (INGR)?

Tate & Lyle shareholders have accepted Ingredion’s recommended all-cash offer, following their board’s support for the deal. According to Ingredion, shareholder approval marks an important milestone toward creating a global ingredient solutions leader with expanded innovation and formulation capabilities.